<DOC>
	<DOC>NCT00599820</DOC>
	<brief_summary>Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks</brief_summary>
	<brief_title>Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks</brief_title>
	<detailed_description>A consecutive case series of patients with angioid streaks that developed subfoveal choroidal neovascularization were treated with a primary 2.5 mg injection of Bevacizumab (Avastin) intravitreally. All patients were evaluated with BCVA at 1, 2 , 4 and 12 weeks and OCT and fluoresceine angiography at month 1 and 3. (Patients will be follow 6 months)</detailed_description>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<mesh_term>Angioid Streaks</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Clinical diagnosis of Angioid Streaks Choroidal neovascularization associated Untreated patients or patients treated once with PDT Ocular surgery excepting uncomplicated phacoemulsification Glaucoma or any other ocular pathology</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Angioid Streaks</keyword>
	<keyword>Choroidal Neovascularization</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>